Jon Gettman

Last updated
Jon Gettman
BornAugust 20, 1957 [1]
Nationality American
Alma mater Catholic University
American University
George Mason University
Known forMarijuana reform activism

Jon B. Gettman (born August 20, 1957) is a marijuana rights activist, a leader of the Coalition for Rescheduling Cannabis, and a former head of the National Organization for the Reform of Marijuana Laws. He has a PhD in public policy and regional economic development from George Mason University and is a longtime contributor to High Times magazine. Gettman filed a petition in 1995 to remove cannabis from Schedule I of the Controlled Substances Act that was eventually denied. A second petition was filed in 2002, with the Coalition for Rescheduling Cannabis, that remains under review by the Department of Health and Human Services. Gettman frequently publishes on the marijuana industry and is an associate professor of Criminology and Criminal Justice at Shenandoah University in Virginia.

Contents

Education

Gettman received a BA in Anthropology from the Catholic University of America and a MS in Justice, specializing in drug policy, from American University. [2] He holds a PhD in public policy and regional economic development from George Mason University, [3] where he is a senior fellow. [4] In addition to his advocacy work, he is an adjunct instructor at Shepherd University in Shepherdstown, West Virginia, teaching public administration. [5]

Advocacy

Gettman is a marijuana reform activist and head of the Coalition for Rescheduling Cannabis. [6] A former director of the National Organization for the Reform of Marijuana Laws, he is a longtime contributor to High Times magazine, where he writes the Cannabis Column. [3] As leader of the Bulletin of Cannabis Reform, he publishes frequently on the marijuana industry. [7]

Medical marijuana

Gettman is a medical cannabis advocate. [8]

Science and the End of Marijuana Prohibition

In 1999, Gettman presented a speech, Science and the End of Marijuana Prohibition, at the 12th International Conference on Drug Policy Reform. He noted that under the Controlled Substances Act, the key decision-makers on marijuana are the scientists at the United States Department of Health and Human Services, whose scientific and medical findings are binding on the Drug Enforcement Administration. Pointing out that Schedules I and II are, by law, reserved for drugs like heroin and cocaine with a "high potential for abuse," Gettman proposed that drug policy reformers use the petitioning process to "cross-examine under oath and penalty of perjury every HHS official and scientist who claims that marijuana use is as dangerous as the use of cocaine or heroin." [9]

Petitions

In 1995 Gettman submitted a petition to the Drug Enforcement Administration calling for the rescheduling of cannabis. The petition sought to remove marijuana and its cannabinoids from Schedules I and II of the Controlled Substance Act on the grounds that the drug lacks the potential for abuse that warrants inclusion there. The DEA must by law forward all petitions which advocate the rescheduling of a drug to the Department of Health and Human Services for further review. [10] By proceeding to do so, the DEA implicitly judged that "sufficient grounds" exist for the rescheduling of cannabis. [11]

In 1999, Gettman speculated that if removed from Schedule I, cannabis could be: [12]

However, upon reviewing the HHS evaluation, the DEA concluded in 2001 that adequate evidence did not exist to necessitate the change. [10] In response, Gettman brought the case before the US Court of Appeals. The court denied the case judicial review because Gettman, not a medical cannabis patient, was unharmed by the DEA restricting access to the drug. [2] Gettman explained that apparently "only those who are actually injured by DEA's refusal to reschedule cannabis have standing to submit DEA's potential actions in this area to judicial review by the federal courts" and organized a coalition to meet this requirement for a subsequent petition. [3]

In October 2002, the Coalition for Rescheduling Cannabis (headed by Gettman [6] and composed of an agglomeration of organizations) filed another petition before the DEA. [3] In April 2002, the DEA formally accepted the proposal, which sought federal recognition of the medicinal value of cannabis, reclassification of the drug, and the establishment of a legal framework for the production and distribution of medical cannabis. In doing so, the DEA acknowledged sufficient merit in the evidence presented in the petition, which focused on accepted medicinal value rather than relative harm, [13] to warrant additional review rather than dismissal. [8] In 2004, the DEA referred the petition to the Department of Health and Human Services for a full-scale evaluation where, as of May 2006, it remains. [13]

The Cannabis Column, a longstanding column on High Times magazine, tracks the progress of this petition. [13] As of September 16, 2009, the column has eclipsed fifty issues. [14]

Studies

Marijuana Production in the United States

In 2006 Gettman wrote a special report, entitled "Marijuana Production in the United States, published in the Bulletin of Cannabis Reform. [15] In it, he estimated the monetary value of the marijuana crop and determined marijuana the largest cash crop in the nation, exceeding the combined values of corn and wheat. [6] Gettman then argues that marijuana prohibition has failed and calls for the legalization and regulation of what he calculated to be a $35.8 billion industry. [5]

Lost Taxes and Other Costs of Marijuana Laws

In 2007 Gettman authored another special report for the Bulletin of Cannabis Reform, entitled "Lost Taxes and Other Costs of Marijuana Laws." [16] The study examined the effects of marijuana prohibition from an economic perspective and calculated that prohibition costs taxpayers approximately $42 billion in enforcement costs and foregone tax revenues. [7]

See also

Related Research Articles

<span class="mw-page-title-main">Drug Enforcement Administration</span> United States federal law enforcement agency

The Drug Enforcement Administration is a United States federal law enforcement agency under the U.S. Department of Justice tasked with combating illicit drug trafficking and distribution within the U.S. It is the lead agency for domestic enforcement of the Controlled Substances Act, sharing concurrent jurisdiction with the Federal Bureau of Investigation, the U.S. Immigration and Customs Enforcement, and U.S. Customs and Border Protection. However, the DEA has sole responsibility for coordinating and pursuing U.S. drug investigations both domestically and abroad.

The Multidisciplinary Association for Psychedelic Studies (MAPS) is an American nonprofit organization working to raise awareness and understanding of psychedelic substances. MAPS was founded in 1986 by Rick Doblin and is now based in San Jose, California.

<span class="mw-page-title-main">Removal of cannabis from Schedule I of the Controlled Substances Act</span> Proposed changes to the legal status of cannabis in U.S. federal law

In the United States, the removal of cannabis from Schedule I of the Controlled Substances Act is a proposed legal and administrative change in cannabis-related law at the federal level. It has been proposed repeatedly since 1972. The category is the most tightly restricted category reserved for drugs that have "no currently accepted medical use."

<span class="mw-page-title-main">National Institute on Drug Abuse</span> Branch of the National Institutes of Health in the United States

The National Institute on Drug Abuse (NIDA) is a United States federal government research institute whose mission is to "advance science on the causes and consequences of drug use and addiction and to apply that knowledge to improve individual and public health."

The Alliance for Cannabis Therapeutics (ACT) is an organization supporting medical marijuana that was founded in 1981 by Robert C. Randall and Alice O'Leary. Randall was the first person known to have successfully used medical necessity as a defense against a charge of marijuana possession in violation of the Controlled Substances Act.

<span class="mw-page-title-main">Legalization of non-medical cannabis in the United States</span> Legalization of marijuana in the United States

In the United States, the non-medical use of cannabis is legalized in 23 states and decriminalized in 8 states, as of May 2023. Decriminalization refers to a policy of reduced penalties for cannabis offenses, typically involving a civil penalty for possessing small amounts, instead of criminal prosecution or the threat of arrest. In jurisdictions without penalty the policy is referred to as legalization, although the term decriminalization is sometimes used for this purpose as well.

<span class="mw-page-title-main">Legal history of cannabis in the United States</span>

In the United States, increased restrictions and labeling of cannabis as a poison began in many states from 1906 onward, and outright prohibitions began in the 1920s. By the mid-1930s cannabis was regulated as a drug in every state, including 35 states that adopted the Uniform State Narcotic Drug Act. The first national regulation was the Marihuana Tax Act of 1937.

<span class="mw-page-title-main">Drug liberalization</span> Process of reducing drug prohibition laws

Drug liberalization is a drug policy process of decriminalizing or legalizing the use or sale of prohibited drugs. Variations of drug liberalization include: drug legalization, drug re-legalization and drug decriminalization. Proponents of drug liberalization may favor a regulatory regime for the production, marketing, and distribution of some or all currently illegal drugs in a manner analogous to that for alcohol, caffeine and tobacco.

<span class="mw-page-title-main">Veterans for Medical Cannabis Access</span>

Veterans for Medical Cannabis Access (VMCA), which was founded as Veterans for Medical Marijuana Access (VMMA) reflecting the pejorative word "marijuana", is an Elliston, Virginia-based non-profit service organization designed to assist American veterans who wish to be able to use marijuana for medical purposes with a doctor's recommendation. VMCA works towards the freedom for veterans to discuss the medical use of marijuana with their doctors without the risk of reprisal.

<span class="mw-page-title-main">Cannabis in the United States</span> Legality, use, culture, market and production of cannabis in the United States

The use, sale, and possession of cannabis over 0.3% THC in the United States, despite laws in many states permitting it under various circumstances, is illegal under federal law. As a Schedule I drug under the federal Controlled Substances Act (CSA) of 1970, cannabis over 0.3% THC is considered to have "no accepted medical use" and have a high potential for abuse and physical or psychological dependence. Cannabis use is illegal for any reason, with the exception of FDA-approved research programs. However, individual states have enacted legislation permitting exemptions for various uses, including medical, industrial, and recreational use.

<span class="mw-page-title-main">Cannabis in Oregon</span> Use of cannabis in Oregon

Cannabis in Oregon is legal for both medical and recreational use. In recent decades, the U.S. state of Oregon has had a number of legislative, legal, and cultural events surrounding use of cannabis. Oregon was the first state to decriminalize the possession of small amounts of cannabis, and among the first to authorize its use for medical purposes. An attempt to recriminalize possession of small amounts of cannabis was turned down by Oregon voters in 1997.

<span class="mw-page-title-main">Medical cannabis in the United States</span> Use of cannabis for medical purposes in the United States

In the United States, the use of cannabis for medical purposes is legal in 38 states, four out of five permanently inhabited U.S. territories, and the District of Columbia, as of March 2023. Ten other states have more restrictive laws limiting THC content, for the purpose of allowing access to products that are rich in cannabidiol (CBD), a non-psychoactive component of cannabis. There is significant variation in medical cannabis laws from state to state, including how it is produced and distributed, how it can be consumed, and what medical conditions it can be used for.

<span class="mw-page-title-main">Dronabinol</span> Generic name of Δ9-THC in medicine

The International Nonproprietary Name dronabinol, also known under the trade names Marinol, Syndros, Reduvo and Adversa, is a generic name for the molecule of delta-9-tetrahydrocannabinol in the pharmaceutical context. It has indications as an appetite stimulant, antiemetic, and sleep apnea reliever and is approved by the FDA as safe and effective for HIV/AIDS-induced anorexia and chemotherapy-induced nausea and vomiting only.

Americans for Safe Access v. Drug Enforcement Administration was a case in which the U.S. Court of Appeals for the D.C. Circuit held that the DEA's denial of a petition by plaintiff Americans for Safe Access for removal of cannabis from Schedule I of the Controlled Substances Act survives review under the deferential arbitrary and capricious standard. 21 U.S.C. § 812(b)(1)(B) requires that cannabis be found to have no "currently accepted medical use" in order to remain in Schedule I. This DEA, pursuant to regulations that the court had approved in Alliance for Cannabis Therapeutics v. DEA, interpreted this to require "adequate and well-controlled studies proving efficacy" in order for cannabis to be removed from Schedule I. The court deferred to the agency's interpretation and found that substantial evidence supported the DEA's determination that such studies do not exist. This case was the third attempt to get the D.C. Circuit to order that cannabis be rescheduled.

<span class="mw-page-title-main">Glossary of cannabis terms</span>

Terms related to cannabis include:

Patients Out of Time (POT) is an American medical cannabis nonprofit organization and patients rights group, established in 1995.

<span class="mw-page-title-main">Cannabis rights</span> Legal protections for marijuana consumers

Cannabis rights or marijuana rights are individual civil and human rights that vary by jurisdiction. The rights of people who consume cannabis include the right to be free from employment discrimination and housing discrimination.

<span class="mw-page-title-main">Cannabis and international law</span>

The status of cannabis in international law is a century-old history. Cannabis reform at the international level refers, in the 20th Century, to efforts to increase restrictions on cannabis use under international treaties; in the 21st Century, generally to efforts to ease or update such restrictions.

<span class="mw-page-title-main">FAAAT think & do tank</span> Global think tank on drug policy reform

For Alternative Approaches to Addiction, Think & do tank is an international non-profit organization working on drug policy, created in 2015 and based in Paris, France.

The removal of cannabis and cannabis resin from Schedule IV of the Single Convention on narcotic drugs, 1961 is a change in international law that took place in 2021, on the basis of a scientific assessment by the World Health Organization.

References

  1. ↑ Gettman, Jon (2008). "Curriculum Vitae" (PDF). ibabuzz.com. Retrieved 2014-12-15.
  2. 1 2 "About DrugScience.org". Bulletin of Cannabis Reform. DrugScience.org. 2006. Retrieved 2009-10-10.
  3. 1 2 3 4 Gettman, Jon (2002-09-05). "The Coalition for Rescheduling Cannabis". High Times. Archived from the original on 2011-07-17. Retrieved 2009-10-10.
  4. ↑ Gettman, Jon (2008-01-08). "Coalition for Rescheduling Cannabis, Jon Gettman comments on DEA/Olsen Ruling" (PDF). drugrehaballiance.com. Archived from the original (PDF) on 2014-12-18. Retrieved 2014-12-17.
  5. 1 2 Sturgis, Sue (2006-12-20). "Marijuana a top cash crop for the South". Institute for Southern Studies. Magazine of the Institute for Southern Studies. Archived from the original on 2011-09-27. Retrieved 2009-10-10.
  6. 1 2 3 Venkataraman, Nitya (2008-12-18). "Marijuana Called Top U.S. Cash Crop". ABC . Retrieved 2009-10-10.
  7. 1 2 Quentin, Hardy (2007-10-01). "Marijuana's $42 Billion Question". Forbes . Archived from the original on October 11, 2007. Retrieved 2009-10-11.
  8. 1 2 Gettman, Jon (2003-04-18). "Formal Acceptance of the Plea". High Times . Archived from the original on 2011-07-17. Retrieved 2009-10-11.
  9. ↑ Gettman, Jon (1999-05-13). "Science and the End of Marijuana Prohibition". Coalition for the Abolition of Marijuana Prohibition. Archived from the original on 2008-04-03. Retrieved 2009-10-11.
  10. 1 2 Shohov, Tatiana (2003). "Medical Use of Marijuana: Policy and Regulatory Issues". Medical use of marijuana: policy, regulatory, and legal issues. Nova Publishers. p. 50. ISBN   978-1-59033-754-7 . Retrieved 2009-10-10.
  11. ↑ Sloman, Larry (1998). "The Madness Continues". Reefer madness: the history of marijuana in America. Macmillan. p. 429. ISBN   978-0-312-19523-6 . Retrieved 2008-10-10.
  12. ↑ Gettman, Jon (1999-07-18). "Marijuana Rescheduling Fund Solicits Contributions". Cannabisnews.com. Retrieved 2009-10-11.
  13. 1 2 3 Gettman, Jon (2006-05-01). "The FDA and Medical Marijuana". High Times . Archived from the original on 2010-06-26. Retrieved 2009-10-11.
  14. ↑ Gettman, Jon (2009-09-16). "Cannabis Column". High Times . Archived from the original on 2008-06-30. Retrieved 2009-10-11.
  15. ↑ Gettman, Jon (December 2006). "Marijuana Production in the United States" (PDF). Bulletin of Cannabis Reform. DrugScience.org. Archived from the original (PDF) on 2008-04-28. Retrieved 2020-04-09.
  16. ↑ Gettman, Jon (2007-09-05). "Lost Taxes and Other Costs of Marijuana Laws" (PDF). Bulletin of Cannabis Reform. DrugScience.org. Archived from the original (PDF) on 2010-12-07. Retrieved 2020-04-09.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.